Skylight Health Group Inc SLHGF

Healthcare Technology Cannabis

Skylight Health Group Inc. is a Canada-based healthcare services and technology company. The Company operates a Florida-based primary care health network comprised of physical practices providing a range of services from primary care, sub-specialty, allied health and laboratory/diagnostic testing. The Company is focused on helping small and independent practices shift from a traditional fee-for-service (FFS) model to value-based care (VBC) through tools, including proprietary technology, data analytics and infrastructure. The Company has two segments related to its medical services and software and corporate businesses, which also align with the two countries in which it operates, namely, United States and Canada. It provides a range of healthcare services, including primary and urgent care, sub-specialists, allied health and wellness, and laboratory/diagnostic testing.

GREY:SLHGF - Post by User

Skylight Health Group Inc > At what point would NASDAQ delist

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Jan 11, 2022 12:56pm

137 Views

Post# 34304282

RE:RE:At what point would NASDAQ delist

Trading at $1.02 US so close to triggering deficiency notice from NASDAQ.....

lscfa wrote: $1.00 US is the threshold.....

Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements

Download as PDF February 28, 2020

LAVAL, Qubec, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG) (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today announced that on February 28, 2020, it received written notification from the Nasdaq Listing Qualifications Department (“Nasdaq”) for failing to maintain a minimum bid price of U.S.$1.00 per share for the last 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2) – bid price (the “Minimum Bid Price Rule”).

The Nasdaq notification has no immediate effect on the listing of Acasti Pharma’s shares. Under Nasdaq Listing Rule 5810(c)(3)(A) – compliance period, Acasti Pharma has 180 calendar days, or until August 26, 2020, to regain compliance. If at any time over this period the bid price of Acasti Pharma’s shares closes at U.S.$1.00 per share or more for a minimum of ten (10) consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed.

If Acasti Pharma does not regain compliance within the initial 180-day period, but otherwise meets the continued listing requirements for market value of publicly-held shares and all other initial listing standards for the Nasdaq Listing Rule 5505 – Capital Market criteria, except for the Minimum Bid Price Rule, Acasti Pharma may be eligible for an additional 180 calendar days to regain compliance. If Acasti Pharma is not granted additional time, then its shares will be subject to delisting, at which time Acasti Pharma may appeal the delisting determination to a Nasdaq Hearings Panel.

Acasti Pharma intends to evaluate all available options to resolve the deficiency and regain compliance with the Minimum Bid Price Rule.

Eppy wrote: I have been invested in this stock from the get go. My current concern is at what point does NASDAQ decide to delist a stock due to poor share price. I hope it doesnt come to that but I am concnerned that if that happens what then. GLTA